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INTRODUCTION 
1. Myotonia 
 Myotonia (myo, muscle; tonus, tension) is defined as delayed relaxation of the 
skeletal muscle after voluntary contraction or mechanical stimulation. This delay results from 
increased excitability of the skeletal muscle plasma membrane.    
 Patients with myotonia experience muscle stiffness. They have, for example 
difficulties releasing a clenched fist, getting up from a chair, or opening their eyes after 
squinting in bright light. They may also have a stiff, awkward gait.  
 Myotonia can affect all muscle groups. However, the pattern of affected muscles can 
vary. The severity of muscle stiffness can be influenced by several other factors (Heatwole 
and Moxley, 2007; Mankodi, 2008), such as emotion (Thomsen, 1876; Gutmann and Phillips, 
1991; Trip et al., 2009), temperature (Thomsen, 1876; Gutmann and Phillips, 1991; Trip et 
al., 2009), exercise (Thomsen, 1876; Colding-Jørgensen, 2005), and pregnancy  (Lacomis et 
al., 1999; Newman et al., 1999; Rudnik-Schöneborn et al., 2006; Trip et al, 2009). In addition, 
myotonia can be found in combination with muscle weakness (Becker, 1977; Trip et al., 
2009). Although myotonia is often described as painless (Heatwole and Moxley, 2007; Miller, 
2008), recent evidence indicates that painful myotonia is relatively common in non-dystrophic 
myotonias (Trip et al., 2009). Myotonia is not lethal. Nevertheless, severely affected 
individuals may be subjected to potentially hazardous situations due to their sudden inability 
to move away.  
 Upon neurological examination myotonic reactions may be observed in the patients 
as action myotonia after voluntary contraction, or/and percussion myotonia after mechanical 
stimulation (Figure 1 and 2). On electromyography (EMG) examination, characteristic 
spontaneous, repetitive electrical discharges called “myotonic runs” can be recorded (Figure 
3). Classic myotonic discharges have a pattern of waxing and waning of both amplitude and 
frequency (Rüdel et al., 1985; Miller, 2008). In addition, the sound profile produced during 
EMG is distinct and typical to myotonia, described as a ‘diving bomb’. In very mild cases, 
EMG may be the only positive sign of myotonia, whereas muscle stiffness or/and clinical 
myotonic reactions might be completely absent. This is called ‘latent myotonia’ (Rüdel et al., 
1985; Lossin and George, 2008).  
  











Figure 1. Action myotonia. The patient was asked to make a forceful fist for several 
seconds (A), and was then asked to open the hand as fast as possible (B). The ability to 
fully extend the fingers and release the handgrip is abnormally delayed. (Pelargonio et 







Figure 2. Percussion myotonia of the thenar muscle. A, A tap was made with a 
reflex hammer on the thenar eminence. B, The myotonic muscle became indented for a 
few seconds without immediate relaxation. (Miller, 2008; with permission from the 
journal:  Muscle Nerve) 
 
 
 EMG examination does not allow a distinction between myotonic disorders. Several 
specialized tests have been developed, combining electrophysiological examinations with 
provoking factors like exercise or cooling. Some studies have shown that combinations of 
these specialized tests may assist in distinguishing phenotypes and accordingly direct the 
relevant molecular genetic investigations (Nielsen et al., 1982; McManis et al., 1986; Sander 
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et al., 1997; Fournier et al., 2004 and 2006; Tan et al., 2011). However, their reliability and 
reproducibility are not completely established. 
                       
Figure 3. ‘Myotonic runs’ on EMG. Normal muscle responds with single action 
potentials upon single stimuli. However, myotonic muscle often responds with a series of 
repetitive action potentials. Notice that both the amplitude and the frequency of the 
myotonic discharges increase and decrease with a waxing and waning pattern. (Provided 
by Dr. Erik Stålberg in Uppsala, Sweden) 
 
 
 Lifestyle modification and avoidance of precipitating factors (such as cold exposure) 
are important in the management of myotonia. Symptomatic treatment of muscle stiffness is 
currently the standard therapy. Agents that block sodium channels are the most commonly 
used (Ceccarelli et al., 1992; Jackson et al., 1994; Savitha et al., 2006; Lyons et al., 2010; 
Logigian et al., 2010). The carbonic anhydrase inhibitor acetazolamide is also frequently 
applied (Trudell et al., 1987; Ferriby et al., 2006). However, lack of good randomized 
controlled studies makes it difficult to evaluate their effect as well as their safety (Trip et al., 
2006). There are currently no drugs available which act directly on the muscle chloride 
channel. However, new therapies are under development (Wheeler et al., 2007; Cleland and 
Grigg, 2008; Matthews et al., 2010).  
  
2. Pathological mechanisms underlying myotonia 
 Physiologically, several pathomechanisms can cause hyperexcitability of the skeletal 
muscle plasma membrane. Three abnormalities have been reported in patients with myotonia: 
1) Reduced muscle chloride (Cl-) conductance (GCl) observed in myotonia congenita (MC) 
and dystrophic myotonia (DM). 2) Alterations of sodium (Na+) currents in sodium 
channelopathy associated with myotonia (NaCh) and DM. 3) Abnormal potassium (K+) 
conductance observed in cultured cells derived from patients with DM (Rüdel et al., 1985). 
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2.1 Action potential 
 When a nerve impulse reaches a muscle cell at the neuromuscular junction, it causes 
a change in the electric potential across the plasma membrane (called action potential). 
Skeletal muscle cells rapidly convert this electrical signal into a rise in cytosolic calcium 
(Ca2+) concentration, which then initiates contraction in each muscle cell (Figure 4). One 
nerve stimulus induces one action potential leading to one muscle contraction.  












Figure 4. Sequential activation of gated ion channels at a neuromuscular 
junction. When a nerve impulse reaches the terminus of a presynaptic motor 
neuron, voltage-gated Ca2+ channels open (step 1) and acetylcholine is released. 
This, in turn, triggers the opening of the ligand-gated nicotinic receptor channels in 
the muscle plasma membrane (step 2), and Na+ ions flow into the muscle cell. The 
influx of Na+ produces a localized membrane depolarization. Voltage-gated Na+ 
channels open (step 3) and allow more Na+ influx, which further depolarizes the 
membrane. When the amplitude of the depolarization reaches the threshold 
(approximately -50 mV), a regenerative potential change known as an action 
potential is crested, which sweep down the length of the entire plasma membrane. 
When the depolarization reaches T- tubules, it activates voltage-gated Ca2+-release 
channels (step 4), and Ca2+ ions release from the sarcoplasmic reticulum (SR) into 
the cytosol. The rise in cytosolic Ca2+ concentration causes muscle contraction. 
(“Molecular Cell Biology”. 4th edition. Lodish H, Berk A, Zipursky SL, Matsudaira 
P, Baltimore D, and Darnell J. New York: W. H. Freeman; 2000; with permission)  
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 Action potentials are mediated by the voltage-gated ion channels embedded in the 
muscle plasma membrane (the sarcolemma). The two primary currents, voltage-gated Na+ and 
K+ current, are the ionic basis of the action potential (Figure 5). They control depolarization 
and repolarization phases of the potential change, respectively. A nerve impulse causes an 
opening of voltage-gated Na+ channels (Na+ ion influx) followed by the activation of voltage-
gated K+ channels (K+ ion efflux). Following an action potential, there is an absolute 
refractory period during which no second action potential can be triggered irrespective of the 
stimulus strength. This is because the Na+ channels have yet to recover from inactivation to 
the closed conformation. The absolute refractory period is followed by a relative refractory 














Figure 5. The action potential. An action potential is a rapid, transient reversal in 
membrane potential mediated by voltage-gated ion channels found in the plasma 
membrane (“Psychology: An introduction”. 11th edition. Charles G. Morris, Albert A. 
Maristo. Prentice-Hall, Inc.; 1995-2002; with permission)  
 
 
2.2 Increased excitability of the muscle and myotonia 
 The threshold potential at which the inward Na+ current exactly balances the outward 
K+ current is a critical potential, as any increase in Na+ influx or reduction in K+ efflux evokes 
subsequent depolarization. The summation of the after-depolarization may be sufficient to 
initiate a self-sustaining action potential. Whereas normal muscles respond with single action 
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potential upon single stimuli, myotonic muscles often respond with runs of action potentials, 
causing extended muscle contractions. In addition, any larger sustained Na+ current could 
produce a prolonged depolarization, which turns the muscle fiber electrically unexcitable. 
This may cause muscle weakness or paralysis (Cannon et al., 1993; Colding-Jørgensen, 
2005).  
Unlike other excitable cells, the resting membrane conductance in normal skeletal 
muscle is dominated by Cl- rather than by K+. The sarcolemma GCl contributes to 
approximately 70-80% of the resting membrane potential. It is essential for the electrical 
stability of the muscle fiber. In its defect or absence, Na+ channels have enough time to 
recover from inactivation while the membrane potential is still depolarized. The most 
important role of the GCl in skeletal muscle might be to counteract the depolarizing effect of 
local K+ accumulation in the T-tubules that accompanies excitation. It contributes 
significantly to the fast repolarization and largely eliminates after-depolarization.  
  A reduction of GCl to 50% apparently does not cause myotonia (Chen et al., 1997). 
Some reports concluded that a 70% or greater reduction of GCl is required to induce myotonia 
in muscle fibers (Barchi, 1975; Kwiecinski et al., 1988).  
 
3. Myotonic disorders  
  Myotonia is a clinical feature associated with a number of neuromuscular diseases. 
Although the myotonic disorders share this symptom, they have different genetic causes. 
Myotonia represents the clinical end point resulting from dysfunctions in a number of 
membrane ion channels. 
 The myotonic disorders can be divided into two main categories: non-dystrophic 
(NDMs) and dystrophic myotonias (DMs) (Table 1). The NDMs are distinguished from the 
dystrophic types by the absence of progressive muscle weakness, dystrophic features in the 
muscle histology, and multisystem involvement. Both categories are clinically highly 
heterogeneous with a wide variety of phenotypes.  
   There are other diseases, such as Schwartz-Jampel syndrome (SJS) and hereditary 
familial episodic ataxia type 1 that can mimic clinical myotonia. However, additional clinical 
symptoms and the lack of characteristic EMG features distinguish these disorders from the 
NDMs. Other conditions, such as acid maltase deficiency, polymyositis, as well as some 
drugs, can occasionally produce myotonic potentials on EMG (Heatwole and Moxley, 2007; 
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Miller, 2008). 
 
Table 1. Myotonic Disorders  
                   Mode of        Gene       Gene              Gene product 
             inheritance    location    symbol              (Protein) 
Non-dystrophic myotonias (NDMs) 
Sodium channelopathy         
  assiociated with myotonia (NaCh)            AD             17q13      SCN4A          skeletal muscle voltage-gated 
Paramyotonia congenita (PMC)                sodium (Na+) channel α-subunit 
Hyperkalemic periodic paralysis (HyperPP)         
Potassium-aggravated myotonia (PAM)    
      
Chloride channelopathy          
  associated with  myotonia (ClCh)      7q35       CLCN1         skeletal muscle voltage-gated 
Myotonia congenita (MC)                 muscle chloride (Cl-) channel 
Thomsen’s myotonia (DMC)                          AD        
      Becker’s myotonia (RMC)                          AR 
Dystrophic myotonias (DMs) 
Myotonic dystrophy                             AD 
type 1 (DM1)                            19q13.3   DMPK      Dystrophic myotonia protein kinase 
type 2 (DM2)                  3q21.3   CNBP/               Cellular nucleic acid 
     Proximal myotonic myopathy(PROMM)       ZNF9                 binding protein gene 
     Proximal dystrophic myotonia (PDM)         
(AD autosomal dominant; AR autosomal recessive; SCN4A, skeletal muscle voltage-gated sodium channel α−subunit 
gene; CLCN1, skeletal muscle voltage-gated chloride channel gene; DMPK, dystrophia myotonica-protein kinase 
gene; CNBP/ ZNF9, CCHC-type zink finger, nucleic acid binding protein gene) 
 
3.1 Non-dystrophic myotonias (NDMs) 
 The NDMs belong to the skeletal muscle ion channelopathies. They are caused by 
dysfunction of the chloride or the sodium channels located in the plasma membranes of the 
muscle cells. They only affect the muscle system with myotonia as the main symptom. 
Despite a growing knowledge of the genetic etiology of these disorders, clinical and 
electrophysiological features remain paramount in diagnosing and differentiating these 
diseases. Family history, myotonia characteristics and its response to stimuli (including cold, 
potassium ingestion, exercise, and drug therapy), EMG features, together with the available 
molecular studies are the diagnostic determinants. However, marked phenotypic differences 
in patients with identical genetic etiology, even between members of the same family, are 
evident in all NDMs. This indicates that other modifying factors may exist. Overall, the 
prognosis is good, with no reduction in life expectancy.  
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3.1.1 Chloride (Cl
-
) channelopathy associated with myotonia (ClCh)  
Myotonia congenita (MC) 
 MC has a prevalence estimated around 1:100,000 worldwide (Emery, 1991). In 
Northern Finland the prevalence was reported to be much higher, about 7.3:100,000 
(Baumann et al., 1998).   
  MC can be transmitted either as a dominant or as a recessive trait.  The dominant 
type was first described in 1876 by Dr. Asmus Julius Thomas Thomsen (Thomsen, 1876) who 
himself had the disease (Thomsen's myotonia, DMC, OMIM 160800). A century later, Becker 
described the recessive form of MC (Becker, 1977) (Becker’s myotonia, RMC, OMIM 
255700). In the majority of the families with MC, the inheritance is thought to be recessive.  
 Both types of MC share two similar clinical signs, muscle stiffness (myotonia) and 
muscular hypertrophy. Muscle stiffness is most pronounced when a forceful movement is 
suddenly initiated after a period of rest, but decreases as the same movement is repeated 
several times ("warm-up" phenomenon). Stiffness is also more pronounced in the extremities, 
especially in the legs and the hands. In general, myotonia in RMC is clinically more severe 
and generalized than myotonia in DMC (Becker, 1977; Mailänder et al., 1996; Rayan and 
Hanna, 2010). The stiffness is usually progressive for a few years after its first appearance and 
then remains stable. Muscular hypertrophy is usually present, particularly in the calves and 
gluteal muscles.  
 In addition to the degree of myotonia, a few other differences between DMC and 
RMC have been described, which may allow clinical differentiation (Becker, 1977; Mankodi, 
2008). DMC is characterized by early onset (from infancy to early childhood), while RMC is 
characterized by a later onset (after the first decade of life) and a commonly presented 
transient muscle weakness. The weakness lasts only seconds to minutes, and especially affects 
the arms and legs. In many patients, the weakness also improves during several minutes of 
continued exercise. Occasionally, permanent muscle weakness and wasting with atrophy of 
selected distal muscle groups may occur in RMC (Becker, 1977; Nagamitsu et al., 2000).  
 Muscle pain is not a typical feature of MC, but it is not uncommon (Fialho et al., 
2007). Mildly elevated serum creatine kinase (CK) levels have been described as common 
(Fialho et al., 2007; Heatwole and Moxley, 2007). Muscle biopsy may show hypertrophic 
fibers, central nuclei, and deficiency in type 2 muscle fibers. None of these findings, however, 
are diagnostic.  
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Skeletal muscle voltage-gated chloride channel gene CLCN1 
 MC is the first recognized inherited chloride channelopathy. Disease causing 
mutations in the major muscle voltage-gated chloride channel gene, CLCN1, were identified 
in 1990s (Koch et al., 1992; George et al., 1993; Lorenz et al., 1994). The CLCN1 gene, 
located on chromosome 7q35, encodes the major voltage-gated skeletal muscle Cl- channel 
(ClC-1). Surprisingly, both types of MC, Thomsen and Becker, are caused by mutations in the 
same gene.   
 To date, over 150 mutations causing MC have been identified in the CLCN1 gene 
(http://www.hgmd.cf.ac.uk/ac/gene.php?gene=CLCN1). The number is continuing to 
increase, illustrating the high degree of allelic heterogeneity associated with this disorder. The 
CLCN1 mutations are spread throughout the whole gene and show no specific locations for 
mutations leading to DMC or RMC. However, exon 8 appeared to harbor clusters of 
mutations that more commonly result in DMC (Fialho et al., 2007). Nevertheless, no clear 
correlation between genotype and phenotype for distinct mutations has been found. Despite 
the numerous mutations identified, CLCN1 mutations were detected in about 40-100% of the 
clinically diagnosed MC patients reported in the literature (Meyer-Kleine et al., 1995; Zhang 
et al., 1996; Sangiuolo et al., 1998; Plassart-Schiess et al., 1998; de Diego et al., 1999; 
Papponen et al., 1999; Deymeer et al., 1999; Fialho et al., 2007; Trip et al., 2008).  
 Although the majority of the CLCN1 mutations are recessively inherited, a few are 
transmitted dominantly (Pusch, 2002; Wu et al., 2002; Jurkat-Rott et al., 2010a). Curiously, 
several mutations were observed to have a variable mode of transmission: they can be 
associated with either RMC or DMC in different families (Pusch, 2002; Colding-Jørgensen, 
2005; Dupré et al., 2009). The molecular mechanism of this complex behavior remains 
unclear. Variable penetrance (Koty et al., 1996; Kubisch et al., 1998), incomplete dominance 
(Plassart-Schiess et al., 1998), differences in allelic expression (Dunø et al., 2004), and lower 
clinical expressivity in females (Becker, 1977; Mailänder et al., 1996; Deymeer et al., 1999) 
have been suggested as possible explanations.  
 CLCN1 mutations have also been identified in other myotonic disorders. 
Heterozygosity for c.2680C>T (p.Arg894X) has been found in a patient with clinical 
hyperkalemic periodic paralysis (HyperPP) (Zhang et al., 1996) and dystrophic myotonia type 
2 (DM2) (Suominen et al., 2008).  
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Skeletal muscle voltage-gated chloride channel (ClC-1) 
 ClC-1 is almost exclusively expressed in skeletal muscle (Steinmeyer et al., 1991). It 
belongs to the highly conserved voltage-gated chloride channel family (ClCs). These Cl- 
channels are expressed in organisms ranging from bacteria and yeast to plants and animals. 
Currently, nine mammalian ClCs have been identified (Jentsch, 2008) and mutations in 
several of them are associated with human diseases.  
 The tertiary and quaternary structures of ClCs are distinct from that of the voltage-
gated cation channels. However, compared with cation channels of similar importance, the 
relationship between structure and function of this channel family is poorly understood. The 
crystal structures of the ClC protein from Escherichia coli (EcClC) and Salmonella 
typhimurium (StClC) have been resolved (Mindell et al., 2001; Dutzler et al., 2002). The 
functional chloride channel exists as a homodimer lined in opposite direction with a "double-
barreled" structure. Each of the subunits contains its own pore, and is made up of 18 α-helical 
regions (Figure 6) of variable length. The gating behavior is complex and consists of two 
main gating modes. The individual pores can open and close independently of one another 
(Duffield et al., 2003; Dutzler, 2004). This is the "fast gate". Both pores are deactivated and 
closed simultaneously by a much slower common gate ("slow gate”) (Duffield et al., 2003; 
Dutzler, 2004). However, the gating mechanisms of ClCs remain poorly understood (Dutzler, 
2004; Jentsch, 2008), and recent electrophysiological studies show that the ClCs seem to be 
functioning as ion transporters as well as ion channels (Jentsch, 2008; Robertson et al., 2010).  
 Functional expression studies have increased the understanding of the nature of these 
channels and the pathophysiology of myotonia (Pusch, 2002). Numerous expression studies 
of the CLCN1 mutations have revealed several mechanisms of altered channel function 
leading to myotonia. Alteration in anion selectivity (Fahlke et al., 1997), inversion of the 
voltage dependence of gating (Fahlke et al., 1995; Zhang et al., 2000a), and shift of the 
voltage dependence of activation to more positive potentials (Pusch et al., 1995; Wagner et 
al., 1998; Zhang et al., 2000b) were described to cause myotonia. It has been proposed that 
CLCN1 mutations causing DMC most probably affect the common gate, whereas mutations 
resulting in RMC involve one of the fast gates (Saviane et al., 1999; Duffield et al., 2003). In 
DMC the mutant subunit exerts a dominant-negative effect over the wild-type subunit by a 
shift in voltage dependence, while in RMC the mutant channel usually show total loss of 
function of both monomers (Pusch et al., 1995; Pusch, 2002). This may explain why 
mutations in the same gene can cause both dominant and recessive disorders, and why 
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recessively inherited myotonia is generally more severe than dominantly inherited myotonia. 
The presence of some normal channels in heterozygous patients with dominantly inherited 
myotonia may result in a residual Cl- current. However, even mutations with 
electrophysiological characteristics consistent with dominant inheritance have been found in 
recessive pedigrees (Kubisch et al., 1998; Pusch, 2002). 











Figure 6. Schematic topology of eukaryotic members of the ClC family. a. The 
topology of the transmembrane domains was deduced from the known structure of the 
bacterial homologue EcClC. ClCs are homodimers with each monomer consists of 16 
transmembrane domains (B-Q). b. View of dimmer interface. Cylinders represent α-
helices. Cords represent loops between helices. (Dutzler, 2002; with permission from the 
journal: Nature) c. "double-barreled" structure of the ClCs with two pores which can 
gate independently (fast gating), while still be connected by a slow common gating. 
(Pusch, 2002; with the permission from the journal: Human Mutation) 
  
  
 Several other voltage-gated chloride channels as ClC-2 and ClC-4 are present in 
skeletal muscle, and with a structure similar to ClC-1. It has been shown that they can form 




) channelopathy associated with myotonia (NaCh)     
 The NaCh mainly includes three disorders, paramyotonia congenita (PMC), 
potassium-aggravated myotonia (PAM), and hyperkalemic periodic paralysis (HyperPP). 
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Clinically, these conditions frequently overlap. Myotonia in patients with PMC is precipitated 
by cold and is aggravated by exercise (paradoxical myotonia). The characteristic of PAM is 
K+-aggravated myotonia. Attacks of muscle weakness are the hallmark of HyperPP.   
 The features that distinguish NaCh from ClCh are the fluctuations in the degree of 
muscle stiffness, and a substantial cold-dependence of the symptoms in the sodium 
channelopathy. Still, the present clinical features of NaCh may be similar to DMC. Trip and 
colleagues (2009) reported that 20% of patients with an initial clinical suspicion of DMC 
were genetically confirmed to have myotonia associated with Na+ channel.   
 Skeletal muscle voltage-gated sodium channel α-subunit gene SCN4A  
 HyperPP, PMC, and PAM are allelic variants of sodium channelopathy. They are 
inherited as autosomal dominant traits, and are associated with mutations in the SCN4A gene 
located on chromosome 17q23 (George et al., 1990 and 1991). This gene encodes the α-
subunit of the voltage-gated skeletal muscle Na+ channel (Nav1.4). To date, around 60 
mutations have been described in the SCN4A gene that cause myotonia 
(http://www.hgmd.cf.ac.uk/ac/gene.php?gene=SCN4A). A certain genotype and phenotype 
correlation exists (Jurkat-Rott et al., 2010b). However, as in Cl- channel myotonia, phenotypic 
variation has been observed in association with the same SCN4A genotype (Matthews et al., 
2010). 
Skeletal muscle voltage-gated sodium channel (Nav1.4) 
 The Nav1.4 contains a larger α-subunit and a smaller β-subunit. The α-subunit forms 
a single ion-conducting pore. The pore contains four domains (I-IV). Each domain comprises 
six transmembrane segments (S1-S6) with interlinking loops (Jurkat-Rott et al., 2010b; 
Matthews et al., 2010) (Figure 7). The fourth segment (S4) of each domain functions as a 
voltage sensor. Upon the change in the membrane potential, the Nav1.4 undergoes 
conformational changes between three states - open, inactivated, and closed state. The 
inactivation conformation prevents further generation of action potential, while the close 
conformation prepares for channel activation upon a new action potential. All three states are 
voltage- as well as time-dependent (Jurkat-Rott et al., 2002). However, the exact mechanisms 
of voltage sensing and the conformational changes are still under investigation (Jurkat-Rott et 
al., 2010b). SCN4A mutations leading to NaCh are thought to be mainly ‘gain-of-function’ 
defects impairing channel inactivation or enhancing channel activation (Celesia, 2001; Jurkat-
Rott et al., 2010b). 
   20 
                                      
Figure 7. Diagramatic outline of the α-subunit of the skeletal muscle 
voltage-gated sodium channel Nav1.4. It contains four domains (I-IV) which 
form a singe pore. Each domain consists of six transmembrane segments. (Matthews 
et al., 2010; with permission from the journal: Brain)   
  
3.2 Dystrophic myotonias (DMs)  
 Myotonic dystrophy (DM) is the most common form of adult muscular dystrophy. 
Currently, it is subdivided into type 1 (DM1, OMIM 160900) and type 2 (DM2, OMIM 
602668) according to their underlying genetic defects. DM1, also called Steinert’s disease, is 
the “classic” type of myotonic dystrophy, first described in 1909 (Steinert, 1909) with a 
prevalence of 2.1-14.2/100.000 worldwide (Harper, 2001). The prevalence of DM2 is 
unknown, though it is thought to be equally prevalent as DM1 (Udd et al., 2003 and 2006). 
However, recent evidence pointed to a higher prevalence of DM2 than expected (Suominen et 
al., 2011). 
 DMs belong to nucleotide repeat expansion disorders. Both types of DM are 
autosomal dominantly inherited, and share similar clinical manifestations. They are 
multisystemic disorders characterized by myotonia, muscle weakness and wasting, muscle 
pain, and involvement of other organs and systems including the eye, heart, endocrine, 
gastrointestinal, and the central nervous system (CNS) (Harper, 2001). DMs shows marked 
clinical variability, similar to NDMs.  
 
3.2.1 DM1 
 The muscle involvement in the classic DM1 is highly characteristic. The core 
features are facial and distal muscle weakness and atrophy. The facial expression in DM1 
patients is characterized by frontal baldness, bilateral ptosis, atrophic temporalis muscles, and 
a long, lean face (Figure 8). The finger-flexor weakness is prominent and distinct. Later in the 
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course of the disease, wasting of the sternocleidomastoid and proximal weakness might 
develop. Muscle biopsies often show type I fiber atrophy, increased number of centrally 








Figure 8. Characteristic facial expression of a patient with DM1. The 
patient showed weakness and atrophy of the facial muscles, wasting of the muscle 
temporalis and ptosis. (Zühlke et al., 2007; with permission from American Journal of 
Medical Genetics)  
 
  As mentioned earlier, several other organ systems are also affected in the classic 
DM1. Posterior iridescent/capsular cataracts are characteristic, and can be detected by slit-
lamp examination. Cardiac involvement, mainly represented by conduction abnormalities is 
common. Rarely, overt clinical manifestations of cardiomyopathy (“myotonic” heart disease) 
are present in patients with DM1 (Pelargonio et al., 2002). Endocrine disturbances with 
abnormal glucose-insulin metabolism, testicular failure, and abnormal growth hormone 
regulation are common (Harper, 2001; Turner and Hilton-Jones, 2010). CNS affection, 
cognitive and behavioral abnormalities (Delaporte, 1998; Turner and Hilton-Jones, 2010), and 
gastrointestinal tract involvements, such as irritable-bowel-like symptoms are common 
(Harper, 2001; Turner and Hilton-Jones, 2010). The life expectancy of most DM1 patients is 
greatly reduced due to respiratory disease, cardiovascular disease, and sudden death 
presumably caused by cardiac arrhythmias (Mathieu et al., 1999; Harper, 2001; Turner and 
Hilton-Jones, 2010). 
 Ten to 15% of DM1 patients have the most severe congenital form with numerous 
developmental abnormalities. They have generalized muscle weakness/hypotonia at birth, 
respiratory insufficiency, craniofacial defects, mental retardation, and a high mortality rate. 
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Myotonia is absent in affected infants, and they do not have cataracts (Harper, 2001; Turner 
and Hilton-Jones, 2010).  
 DM1 is subject to anticipation, elucidating earlier onset and/or more severe 
symptoms in affected individuals belonging to successive generations of the same family 
(Harper, 2001; Turner and Hilton-Jones, 2010).  
Dystrophia myotonica-protein kinase gene DMPK 
  The underlying genetic defect in DM1 is an expansion of a CTG trinucleotide repeat 
motif in the 3'-untranslated region (3' UTR) of the dystrophia myotonica-protein kinase gene, 
DMPK, located on chromosome 19q13.3 (Fu et al., 1992; Mahadevan et al., 1992; Brook et 
al., 1992).  
 There is a general correlation between the degree of expansion and the severity of the 
disease (Harper, 2001; Turner and Hilton-Jones, 2010). The number of repeats ranges from 5 
to 37 in normal individuals. Minimal symptoms are present in people with 50 to 90 repeats 
(premutation), and severely affected patients have larger expansions with as many as 2000 
repeats in the congenital forms (Harper, 2001; Turner and Hilton-Jones, 2010). Currently, the 
golden standard for diagnosis of DM1 is the identification of an abnormal (CTG)n expansion 
in the DMPK gene.  
Dystrophic myotonia protein kinase 
 The DMPK gene encodes a member of the serine-threonine kinase family that 
interacts with members of the Rho family of small GTPases. Several alternatively spliced 
isoforms of the dystrophic myotonia protein kinase (DMPK) have been described (Oude 
Ophuis et al., 2009). It was found that in animal model DMPK was pronouncedly expressed 
in both the skeletal and smooth muscle as well as neural tissues that are commonly affected in 
DM1 (Oude Ophuis et al., 2009). However, the exact function of DMPK is currently 
unknown. It was suggested that this protein may regulate the cytoskeleton reorganization and 
intracellular trafficking process (Kaliman and Llagostera, 2008). 
 
3.2.2 DM2 
 As early as the late 1970s, some neurologists identified patients who did not present 
with the typical features of classical DM. However, it was not until the genetic cause behind 
the classical DM was identified, that a new disease entity was discovered. In 1994, Thornton 
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et al. and Ricker et al. independently reported atypical DM patients without (CTG)n expansion 
in the DMPK gene. Since then, many similar cases with different degrees of severity have 
been described worldwide. They were named proximal myotonic myopathy (PROMM) 
(Thornton et al., 1994; Ricker et al., 1994), proximal myotonic dystrophy (PDM) (Udd et al., 
1997), and DM2 (Ranum et al., 1998; Day et al., 1999). These disorders were shown to have a 
common genetic etiology (Udd et al., 2003) and are now collectively termed myotonic 
dystrophy type 2 (DM2).  
 Currently, our knowledge and understanding of the natural history of DM2 and its 
full spectrum of clinical manifestations remain incomplete. DM2 patients present with 
features resembling of DM1, including muscle weakness and wasting, myotonia, cataract and 
a whole range of manifestations of variable degree in other organ systems. DM2 differs 
principally from DM1 by its late onset, predominant weakness and atrophy of proximal 
muscles at onset, absence of a congenital form, doubtful anticipation, and its milder system 
symptoms with a more favorable long-term prognosis (Day et al., 2003; Schara and Schoser, 
2006; Turner and Hilton-Jones, 2010) (Table 2). The onset of DM2 is typically in the third 
decade. The muscle weakness at onset typically affects the proximal muscle groups, neck and 
elbow flexor and especially hip flexors (Schara and Schoser, 2006; Turner and Hilton-Jones, 
2010). Facial weakness is less common. Some features, such as myalgia, hyperhidrosis and 
hyperinsulinaemia, are reported to be more common in DM2 than in DM1 patients (Schara 
and Schoser, 2006; Turner and Hilton-Jones, 2010). Although no reports on DM2 cases gave 
clear evidence of a congenital form, anticipation has been described in few DM2 families 
(Schneider et al., 2000; Day et al., 2003). Most DM2 patients do not experience severe 
disabilities in their life. Respiratory failure usually does not occur (Meola and Moxley, 2004). 
Sudden cardiac arrest seems uncommon, but has been reported occasionally in younger 
patients (Moxley et al., 2002).  
CCHC-type zinc finger, nucleic acid binding protein gene CNBP  
  DM2 is associated with a CCTG tetra-nucleotide expansion located in intron 1 of the 
CCHC-type zinc finger, nucleic acid binding protein gene, CNBP, previously called ZNF9, 
located on chromosome 3q21.3 (Liquori et al., 2001). Thus, similar to DM1, the repeat motif 
is located in an untranslated region of its respective gene (Table 2). Although DM2 is 
generally a milder disease than DM1, the DM2 (CCTG)n expansions can be much larger than 
DM1 (CTG)n expansions with alleles ranging in size from ~75 to 11,000 CCTG repeats (mean 
~5000 CCTGs) (Udd et al., 2003) (Table 2). The smallest pathogenic repeat size has not been 
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determined. There does not seem to be any correlation between the size of expansion and the 
disease severity, nor with the age of onset (Udd et al., 2003). Moreover, there is no report that 
there exists a pool of premutation alleles in the DM2 population. However, Bachinski and 
coworkers (2009) recently suggested that uninterrupted (CCTG)22-23 allele may represent such 
reservoir for DM2 disease mutations. 
   
      Table 2.  DM1 and DM2 




Localization of mutation 




Muscle weakness/atrophy at onset 





CTG repeat expansion 
3'-UTR 
 37-5000 
Dystrophic myotonia  
protein kinase  
Signal pathway? 
Facial and distal involvement 




CNBP (ZNF9), 3q21.3 
CCTG repeat expansion 
Intron 1 
75-11 000 
Cellular nucleic acid  
binding protein 
Transcriptional / Translation regulation? 
Predominant proximal involvement, milder  
+, but in milder degree 
+  
− 
(Modified from Finsterer, 2002) 
 
 
Cellular nucleic acid binding protein   
  Cellular nucleic acid binding protein (CNBP) is abundantly expressed in human 
muscle fibers (Massa et al., 2010). As for DMPK, the exact functional role of this protein is 
currently unclear. CNBP is a conserved single-stranded nucleic acid binding protein with a 
wide range of targets. Recent data proposed that this protein probably acts as a transcriptional 
and/or translational regulator (Gerbasi and Link, 2007; Schneider-Gold and Timchenko, 
2010), operating as a nucleic acid chaperone (Calcaterra et al., 2010). 
  
3.2.3 Pathomechanisms 
 The underlying molecular mechanism by which the expanded repeat tract produces 
the complex DM1 phenotype is poorly understood. The key question is how does a mutation 
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in the non-coding region of a gene exert a multisystem effect at the cellular level? Three 
possible mechanisms have been suggested based on molecular investigations: 
haploinsufficiency caused by the respective disease gene, chromatin structure alteration 
causing abnormal expression of neighboring genes, and RNA processing related pathogenesis. 
The identification of DM2 as the first tetranucleotide expansion disease threw more insight 
into the molecular pathomechanisms of DMs. The overlapping symptoms suggested that the 
underlying pathomechanisms may be common for both disorders. The function of CNBP 
appears unrelated to DMPK or any of the proteins encoded in the DM1 region of chromosome 
19. Similarly, the other genes in the DM2 region bear no obvious relationship to genes at the 
DM1 locus. It is now generally agreed that both DMs are mainly RNA-mediated diseases 
caused by a dominant negative effect on the expression of other genes or their products. 
(Ranum and Day, 2002; Osborne and Thornton, 2006; Wheeler and Thornton, 2007) (Figure 
9). 
                         
Figure 9. Molecular pathogenesis of DM1 and DM2. Three models have been suggested to be 
involved in DM pathogenesis. The main mechanism is the abnormal RNA processing which leads to 
aberrant splicing of a group of genes, such as CLCN1 and IR. Reduced expressions of the gene 
products of the respective genes of DM1 and DM2 are also implicated. Furthermore, altered 
expression of the neighboring gene(s) of DMPK may also be involved in some of the clinical 
presentations in DM1. hnRNP, human nuclear ribonucleoprotein; MBNL, muscleblind-like protein; CUG-BP, 
CUG binding protein; IR, the Insulin receptor gene; TNNT2, the cardiac Troponin T gene; NMDAR1, the 
Nmethyl-D-aspartate receptor 1 gene; Tau, microtubule-associated protein gene;  APP, the amyloid precursor 




Altered transcription  
of neighboring genes 
Haploinsufficiency   
of the disease genes 
Missplicing of  
a group of genes 
CLCN1                         Myotonia 
IR                                 Insulin resistance 
TNNT2            Cardiac abnormalities?        
NMDAR1/Tau/APP      CNS effects? 
RYR1/MTMR1        Muscle weakness and wasting 
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 The toxic gain-of-function at the RNA level of the DMPK and CNBP encoded RNA 
was suggested based on the observation that both DM1 and DM2 cells exhibit multiple 
nuclear foci if mutant RNA is present. Both genes are transcribed into aberrant RNAs 
containing expanded CUG or CCUG repeat tracts. The aberrant RNAs accumulate in the 
nuclei foci, sequester and alter the regulation or localization of RNA-binding proteins such as 
muscleblind-like protein (MBNL), and CUG binding protein (CUG-BP), which in turn lead to 
aberrant splicing of a group of other genes (Figure 9). Some of the potential pre-mRNA 
targets known are: CLCN1 (Charlet-B et al., 2002; Mankodi et al., 2002; Lueck et al., 2007; 
Wheeler et al., 2007; Botta et al., 2008), IR (Insulin receptor) (Savkur et al., 2001 and 2004; 
Botta et al., 2008), and TNNT2 (cardiac troponin T) (Philips et al., 1998; Botta et al., 2008).  
 However, RNA processing defects alone cannot explain the entire disease pathology 
of DMs (Figure 9). The phenotypic difference between DM1 and DM2, especially the lack of 
developmental abnormalities in DM2 as there were no convincing congenital cases reported, 
suggested that other cellular and molecular pathways may also be involved. Dmpk deficient 
mice display a late-onset myopathy (Reddy et al., 1996), atrioventricular conduction 
abnormalities (Berul et al., 1999), and impaired glucose-insulin metabolism (Llagostera et al., 
2007). Haploinsufficiency of Znf9 in mice mimicked phenotypes resembling DM including 
myotonia, heart arrhythmia, and muscle histopathology (Chen et al., 2007). CTG repeat 
expansions were shown to reduce expression of the neighboring gene SIX5 (Thornton et al., 
1997), and mice deficient in Six5 develop cataract (Klesert et al., 2000; Sarkar et al., 2000). 
These data suggested that all three models may contribute to the DM phenotypic variability. 
However, it is unclear if these three processes are independent or interact. The exact 
mechanism underlying DM is still unknown.  
  
3.2.4 Other types of DM  
 There is still reason to believe that there are multiple genetic causes underlying the 
growing number of families with variable myotonic dystrophy-like symptoms with or without 
additional features. Several families have been reported with similar DM clinical features, but 
showing no linkage to the DM1 or DM2 locus (Udd et al., 2003; Meola et al., 2004). Finding 
additional genes involved in the non-classical forms of DM will greatly enhance our 
understanding of the pathological mechanisms leading to the complex DM phenotype.  
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4. Summary 
 As illustrated above myotonia is a clinical feature seen in several disorders which 
show extensive overlapping phenotypes. Accordingly, it may be challenging to reach the most 
likely clinical diagnosis. Below, an algorithm is presented suggesting a possible strategy to 
find the most reliable clinical diagnosis for a patient presenting with myotonia, and to 
























Figure 10. Clinical diagnosis of myotonic disorders. The clinical evaluation of myotonia 
should be supplied with EMG examination. The provocative factors of muscle stiffness and 
features of myotonic runs on EMG may further direct to sodium or chloride channel myotonia. The 
existence of symptoms from system(s) other than the muscle frequently differentiates the DMs 
from NDMs. Predominant proximal muscle weakness at the onset together with mild course of the 
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AIMS OF THE STUDY 
 
 In Northern Norway, with a population of ~465 000, at least 15 families have been 
clinically diagnosed with MC (Appendix I). The main goal of this project was to assess the 
disease etiology of MC in this population, to improve the diagnostic strategy and genetic 
counseling for patients with myotonia, as well as to improve the biological understanding of 
the myotonia and myotonic diseases.  
 
GOALS:  
1) To determine the prevalence of myotonia congenita (MC) and to study the spectrum of 
CLCN1 gene mutations in the MC population of Northern Norway.  
2) To develop efficient PCR-based methods for molecular diagnosis for MC causing CLCN1 
mutations.  
3) To determine the carrier frequency of CLCN1 mutations in Northern Norway  
4) To increase our understanding of the relationship between mutations in the CLCN1 gene 
(genotype) and the clinical presentation and mode of inheritance (the phenotype). 
 
SUBGOALS: 
1) To study the functional implications of a new CLCN1 mutation c.991G>A (p.Ala331Thr) 
on ClC-1 in an in vitro system in order to improve our understanding of the chloride channel 
protein and, hence, the molecular pathogenesis of MC. 
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STRATEGY 
Clinical investigations 
 Eighteen families with clinical diagnosed MC were included in this study (Appendix 
I): fifteen families from Northern Norway and three families from Northern Sweden. A 
thorough neurological examination and EMG evaluation of the Norwegian patients as well as 
their first-degree relatives (sibs, children, and parents) were performed by one neurologist 
(Dr. T. Torbergsen) with more than thirty years experience in diagnosing myotonia. Grip 
myotonia and percussion myotonia were examined. ‘Warm-up’ phenomenon and cold 
sensitivity were tested. The facial expression as well as muscle hypertrophy or atrophy were 
registered. The muscle strength and reflexes were assessed. Organ involvements other than 
the muscle system were investigated. Slit-lamp examination, electrocardiography (ECG), 
eccocardiomyography, muscle biopsy, and cerebral computer tomography (CT) scan were 
performed when indicated. Blood samples were investigated for the Creatine Kinase (CK), 
Gamma-glutamyl Transpeptidase (γ-GT), Aspartate Aminotransferase (ASAT), Alanine 
Aminotransferase (ALAT), and Lactate Dehydrogenase (LD). Blood glucose, Thyroid-
Stimulating Hormone (TSH), free Thyroxine (FT4), Follicle-Stimulating Hormone (FSH), 
Luteinizing Hormone (LH), and testosterone level were tested when indicated.  
 EMG was performed by concentric needle electrode using Keypoint EMG equipment 
(Medtronic, Denmark). Four muscles were examined: the extensor digitorum communis, the 
dorsal interosseous I, the vastus lateralis, and the anterior tibial muscles. Myotonic discharges 
were recorded, and the motor unit potentials were analyzed for amplitude, durations and early 
recruitment.  
 The clinical and EMG myotonia were further classified in four categories (+/-, +, ++, 
and +++) depending on the degree of affection (suspected, mild, moderate, and pronounced). 
Presence of myotonic runs on EMG was the criteria for being classified as affected. 
  The clinical information regarding the Swedish patients was provided by the local 
physicians.  
  Informed consent was obtained and the study was approved by the Regional 
Committee for Medical and Health Research Ethics. 
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Molecular investigations  
  The methods for molecular investigation of family material are outlined in Figure 11. 
Briefly, genomic DNA was extracted from peripheral blood cells. All 23 exons of the CLCN1 
gene were amplified from DNA from proband(s) of each family. PCR products were then 
screened for mutations by single-stranded conformational polymorphism (SSCP) at three 
different conditions. Abnormal SSCP conformers were reamplified and subsequently 
sequenced. For exons showing normal SSCP patterns, PCR products were directly sequenced. 
Once nucleotide changes were identified, restriction enzyme digestion strategies or 
amplification refractory mutation system (ARMS) were designed and used to screen other 
family members in the respective family and normal controls.  
  For probands with no or only one single CLCN1 mutation, Southern blot analysis was 
performed to check for large deletions, insertions and rearrangements in the CLCN1 gene that 
could have been missed by PCR-based methods. If Southern blot analysis showed normal 
results, haplotype analysis and/or linkage analysis of the DNA samples were performed, to 
check for linkage of the myotonia to the CLCN1 gene. In the families where the disorder was 
excluded to be co segregating with markers in the CLCN1 locus, molecular analysis of SCN4A, 
DMPK and CNBP gene were performed.  
  The pathomechanism of a novel CLCN1 mutation was subsequently studied by in vitro 
functional expression performed in embryonic kidney cells (HEK) and tsA201 cells (a simian 
virus 40 (SV40) T-antigen-expressing derivative of the embryonic kidney cell line HEK-293). 
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SUMMARY OF PAPERS 
 
Paper I. Spectrum of CLCN1 mutations in patients with myotonia congenita in Northern 
Scandinavia. 
In order to explore the spectrum of CLCN1 mutations in Northern Scandinavia the entire 
CLCN1 gene was investigated in 15 Northern Norwegian families and 3 Northern Swedish 
families clinically diagnosed with myotonia congenita (MC). The prevalence of MC in 
Northern Norway was estimated to be as high as about 9:100 000. Eight different CLCN1 
mutations (c.180+3A>T (c.IVS1+3A>T), c.979G>A (p.Val327Ile), c.920T>C (p.Phe307Ser), 
c.991G>A (p.Ala331Thr), c.1238T>G (p.Phe413Cys), c.1592C>A (p.Ala531Val), 
c.2284+5C>T, and c.2680C>T (p.Arg894X)) and three polymorphisms (c.261C>T 
(p.Thr87Thr), c.2154T>C (p.Asp718Asp), and c.2180C>T (p.Pro727Leu)) were identified. 
The p.Phe413Cys, p.Ala531Val, and p.Arg894X substitution clearly predominated in our 
patient population. The p.Ala531Val has been detected only in the populations of Northern 
Norway and Northern Finland whereas the p.Arg894X causing mutation is one of the most 
common CLCN1 mutations found in the MC population worldwide. The allele frequencies of 
c.1238T>G (p.Phe413Cys), c.1592C>A (p.Ala531Val), and c.2680C>T (p.Arg894X) were 
<0.005%, 0.3% and 0.89%, respectively. Heterozygous carriers of c.2680C>T (p.Arg894X) in 
our study are rarely affected by myotonia, in contrast to other reports where c.2680C>T 
(p.Arg894X) has been shown to follow either dominant or recessive inheritance in different 
families. As previously reported there was no obvious genotype - phenotype correlation. This 
may partially be due to the fact that the majority of our patients were compound heterozygous 
with various combinations of different mutations, the c.1592C>A (p.Ala531Val) / c.2680C>T 
(p.Arg894X) being the most frequent. Moreover, three CLCN1 mutations were present in two 
probands. Despite the sequencing of the entire CLCN1 gene in 19 probands from 18 unrelated 
MC families, bi-allelic mutations were detected in 15 probands and mono-allelic mutations in 
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Paper II. The myotonia congenita mutation A331T confers a novel hyperpolarization-
activated gate to the muscle chloride channel ClC-1. 
Mutations in the CLCN1 gene might cause both autosomal dominant and autosomal recessive 
form of myotonia congenita (MC). Numerous CLCN1 mutations have been identified 
scattered over the whole length of the gene. In this study, the functional implication of a novel 
disease-causing CLCN1 mutation c.991G>A (p.Ala331Thr) was investigated using a 
heterologous expression system. The p.Ala331Thr causing mutation was introduced into a 
plasmid vector containing the full-length wild-type (WT) hClC-1 cDNA by site-directed 
mutagenesis. The mutant and WT hClC-1 channel proteins were expressed in human 
embryonic kidney (HEK) 293 and tsA201 cells both in homodimeric and heterodimeric 
forms. Whole-cell patch-clamp recordings were then performed under different conditions. 
The current responses, the gating properties, and the voltage dependence of the studied 
channel were analyzed. The p.Ala331Thr mutant channel in homodimeric form had a novel 
effect on ClC-1 gating. It is the first mutation reported to produce a slow hyperpolarization-
induced gating step in ClC-1 without obvious alterations of the typical deactivation gating of 
this isoform. This slow gating reduces the open probability of mutant channels, explaining the 
myotonic phenotype in muscle fibers expressing the mutant channels. In contrast, 
heterodimeric channels consisting of WT and the mutant ClC-1 subunits do not exhibit this 
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Paper III. Proximal myotonic myopathy: clinical and molecular investigation of a 
Norwegian family with PROMM. 
In 1994, proximal myotonic myopathy (PROMM) was established as a new entity with 
clinical features similar but much milder than myotonic dystrophy (DM1) and without the 
(CTG)n repeat tract expansion in the DMPK gene. Yet, its full clinical spectrum was 
uncertain. A new gene locus, termed DM2, on chromosome 3q was identified in 1998. We 
described the clinical characteristics of the first Norwegian PROMM family. The clinical 
features were inherited as an autosomal dominant trait. The affected family members had 
muscle weakness, myotonia, cataract, and normal (CTG)n repeat size in the DMPK gene. The 
patients had prominent proximal muscle weakness and wasting. The onset of muscle 
weakness was around the third decade rather than fifth to seventh decade as previously 
reported. The male patients in the family had also frontal balding. The female proband had 
ptosis, and her facial, jaw and swallowing muscles were also affected. Myalgia was a 
prominent feature in all affected family members. In addition, central nervous system 
involvement such as hypersomnia, previously rarely described in PROMM, was also present. 
The p.Arg894X causing CLCN1 mutation was found in heterozygous form present in affected 
as well as unaffected family members. Haplotype analysis seemed to exclude the new DM2 
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Paper IV. Myotonia congenita and myotonic dystrophy in the same family: coexistence 
of a CLCN1 mutation and expansion in the CNBP (ZNF9) gene.   
Myotonia is a clinical feature shared by several neuromuscular disorders. They are mainly 
classified into non-dystrophic and dystrophic myotonias. All myotonic disorders are clinically 
highly variable, and it is not always straightforward to distinguish these disorders from each 
other. The mechanisms underlying this clinical heterogeneity are unclear. We investigated a 
unique Norwegian family that was previously diagnosed with myotonic congenita (MC) and 
myotonic dystrophy (DM1) in different branches of the family. In one branch, all female 
patients had myotonia as the main symptom with onset during pregnancy and not 
disappearing after delivery. However, one of their uncles had bilateral cataracts, heart 
manifestation and other system involvement in addition to mild myotonia. Detailed clinical 
evaluation and EMG examination were performed. All known genes associated with 
myotonia were investigated. It turned out that this family had DM2 as a pathological (CCTG)n 
expansion in the CNBP (previously known as ZNF9) was identified in all affected family 
members but in none of the healthy individuals. Our study confirmed that DM2 was 
associated with clinical variability, even within the same family. Furthermore, our study 
indicated that some modifying factors, for example, a hormonal influence may exist that 
contribute to the high phenotypic variations in DM2. A p.Phe413Cys causing CLCN1 
mutation was also identified in this family. This mutation was found in 6 out of 13 affected 
family members, and we found more severe clinical affection in patients harboring both the 
DM2 expansion and p.Phe413Cys variation. Hence, p.Phe413Cys was likely to exaggerate the 
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DISCUSSION  
 
Allelic spectrum and prevalence of myotonia congenita (MC) in Northern Norway  
 More than 150 disease associated CLCN1 mutations have been identified 
(http://www.hgmd.cf.ac.uk/ac/gene.php?gene=CLCN1). In several MC populations of 
different origin a high number of different CLCN1 mutations have been identified (Meyer-
Kleine et al., 1995; Fialho et al., 2007; Trip et al., 2008).  
 In our study on MC in Northern Norway, we found eight different CLCN1 mutations 
(paper I), in contrast to the Finnish MC population (Papponen et al., 1999) where only three 
CLCN1 mutations were found (c.1238T>G (p.Phe413Cys), c.1592C>A (p.Ala531Val), and 
c.2680C>T (p.Arg894X)). However, these three mutations clearly predominated in MC 
patients from Northern-Norway/Sweden, constituting 26 of the total 33 mutant CLCN1 alleles 
detected (paper I). The p.Ala531Val causing mutation has been detected exclusively in the 
Northern Fennoscandian population, while the p.Phe413Cys and p.Arg894X causing 
mutations are the most common CLCN1 mutation detected worldwide.  
 We found a prevalence of about 9:100,000 of MC in Northern Norway (paper I), 
approximately ten fold higher than what has been reported in other populations (Emery, 
1991). This prevalence is probably still an underestimate because very mild cases may remain 
unrecognized and, hence, never diagnosed. The high prevalence found in our study is 
comparable to that in the population of Northern Finland (Baumann et al., 1998).  The genetic 
epidemiological observations from other diseases in the Finnish population (de la Chapelle, 
1993) have shown that enrichment of various disease-causing mutations, through founder 
effects and genetic drift, in the relatively isolated, immobile populations has resulted in the 
accumulation of certain rare diseases. This may be the cause for the high prevalence of MC in 
the Northern Finnish population. The population of Northern Finland has an interesting 
migration history, as reflected in the molecular and genealogical studies of the autosomal 
recessive disorder Aspartylglucosaminuria (AGU) (Tollersrud et al., 1994). The Norwegian 
AGU families originated mostly from Finnish immigrants from the Tornio valley area (North-
West Finland at the border between Northern Finland and Sweden) who migrated in the 
period between 1700 and 1900. They settled mainly in the Western part of Northern Norway, 
in the counties of Troms and Finnmark (Tollersrud et al., 1994). Most of the MC cases 
reported in Northern Finland show similar geographic locations as those of the ancestors of 
Norwegian AGU patients (Baumann et al., 1998; Papponen et al., 1999; Tollersrud et al., 
1994). Hence, it is not unlikely that MC causing mutations, c.1592C>A (p.Ala531Val) in 
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particular, may share a similar migration history with that of the AGUFin mutation. 
Combination of founder events and genetic drift resulting in high carrier frequencies in 
specific sub-populations may explain the high prevalence of MC in Northern Norway. 
However, thorough haplotype analysis with validated SNP markers is required to verify the 
possibility of founder events. Founder investigations in other regions of Scandinavia or in the 
European Caucasian population are largely lacking at this time. 
 
Genotype / phenotype relationships in MC 
 The phenotype of genetic disease such as MC can be considered in several ways: as 
the mode of inheritance, as the clinical features, and as the assessment of mutant channel 
function. A detailed analysis of clinical features was beyond the scope of this work. 
Therefore, only phenotypic aspects related to results from needle EMG examination and mode 
of inheritance are discussed here. The diagnostic methods and criteria are crucial in MC 
classification. Many of the investigations, including the Finnish (Papponen et al., 1999), the 
British (Fialho et al., 2007), and the Dutch (Trip et al., 2008) studies, define a clinical 
diagnosis of MC when a patient has muscle stiffness and/or clinical myotonia confirmed by 
needle EMG examination. How the asymptomatic individuals with electrical myotonia were 
classified - as healthy or affected was not clearly outlined. EMG has been proven to be the 
most reliable diagnostic tool in the clinical assessment of myotonia. Therefore, we used 
positive electrical myotonia on EMG as the only criterion for defining affected status, 
regardless of the existence of muscle stiffness and/or clinical myotonia. This would not only 
include those patients who remain unnoticed of their very mild symptoms, but also patients 
with electrical myotonia as the only sign at the initial investigation, who are likely to develop 
symptoms later on. 
 Several aspects of MC complicate the analysis of inheritance pattern. First, the 
pedigree can be misinterpreted due to pseudodominance as discussed later. Secondly, 
incomplete dominance with variable penetrance or expressivity may further confuse the 
picture (Plassart-Schiess et al., 1998). Lastly, most of the earlier studies of mutation analysis 
in the CLCN1 gene were based on a PCR-SSCP strategy with a low mutation detection yield 
(Meyer-Kleine et al., 1995; Zhang et al., 1996; Sangiuolo et al., 1998). This may to some 
extent explain why some apparently ‘dominant’ mutations have later been shown to be 
‘recessive’. Recent studies have shown that CLCN1 mutations may coincidentally be detected 
in DM2 patients (papers III and IV; Mastaglia et al., 1998; Lamont et al., 2004; Suominen et 
   38 
al., 2008) who may clinically resemble DMC. In these patients, CLCN1 mutations might 
contribute to the intra-familial phenotypic variability. 
 In this work we have identified eight different CLCN1 mutations (c.180+3A>T 
(IVS1+3A>T), c.979G>A (p.Val327Ile), c.920T>C (p.Phe307Ser), c.991G>A (p.Ala331Thr), 
c.1238T>G (p.Phe413Cys), c.1592C>A (p.Ala531Val), c.2284+5C>T, and c.2680C>T 
(p.Arg894X)) (paper I). No apparent cluster of mutations causing DMC or RMC was evident 
in our study (paper I). Fialho and co-workers (2007) reported that exon 8 seemed to harbor 
mutations mostly involved in DMC. Exon 8 encodes the H and I helix, the H − I interlink and 
part of the I − J interlink (Figure 6). The helices H, I, P, and Q form the interface of the 
channel dimer (Duffield et al., 2003), and CLCN1 mutations causing DMC were thought to 
exert their dominant negative effects by abolishing dimer formation with the WT subunit. 
However, several other mutations located in exon 8 were found to cause RMC (Pusch, 2002). 
The p.Phe307Ser causing mutation (paper I, corrigendum) was previously reported to cause 
both RMC and DMC (Kubisch et al., 1998; Colding-Jørgensen et al., 2003). Although 
phenylalanine at position 307 is not highly conserved within the ClCs, a change from a 
nonpolar, hydrophobic phenylalanine to a polar amino acid, serine, might affect the channel 
function as this residue is situated in the I helix. We assumed the p.Phe307Ser was causing 
RMC as it was detected in a proband who harbored three CLCN1 mutations (Figure 1c, paper 
I), heterozygous p.Phe307Ser causing mutation in combination with homozygosity for 
another putative ‘recessive’ splicing mutation c.2284+5C>T (Figure 1c, paper I). The 
c.2284+5C>T variant was absent in 100 control chromosomes. However in retrospect, the 
phenotypic effect of p.Phe307Ser has to be reconsidered. The fact that thymine (T) was found 
in +5 position in other CLCN1 exon/intron junctions makes c.2284+5C>T doubtful as a 
disease causing mutation. Furthermore, recent data available from Ensemble 
(http://www.ensembl.org/index.html) show that the c.2284+5C>T variant has an allele 
frequency of 0.056. This excludes c.2284+5C>T as a disease causing mutation. Thus, it is 
likely that the p.Phy307Ser substitution causes DMC (S03, Appendix) rather than RMC. 
Consequently, the novel p.Ala331Thr substitution is also causing DMC (N05, Appendix), not 
RMC, since it was found in compound heterozygosity with the benign c.2284+5C>T variant 
(N05, paper I). A previously reported G to A substitution at nucleotide position c.979 
(potential p.Val327Ile substitution), at the boundary of exon 8 (Lorenz et al., 1994) was also 
detected. This mutation affects a consensus splice site of the CLCN1 gene and it was 
presumed to lead to myotonia by acting as a donor splice-site mutation (Lorenz et al., 1994). 
Using the splice site prediction program, NNSPLICE 0.9 
(http://www.fruitfly.org/seq_tools/splice.html), c.979G>A was indeed predicted to disrupt the 
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donor splice site. Hence, it is likely that this mutation is disease causing and involved in 
RMC. Another putative splicing mutation c.180+3A>T was predicted not to interfere with 
splicing, according to the NNSPLICE 0.9 program. However, cDNA analysis is needed to 
determine whether these mutations disrupt normal splicing of the CLCN1 gene transcript.  
 The p.Phe413Cys causing mutation showed the most consistent results in our studies. 
None of the individuals heterozygous for the p.Phe413Cys substitution was affected by 
myotonia (paper I), which is in accordance with the fact that it has been reported only as an 
RMC causing mutation in the literature. 
 The p.Arg894X causing sequence variant has been reported in several studies to give 
a dual mode of inheritance in MC (Meyer-Kleine et al., 1995; Zhang et al., 1996; Plassart- 
Schiess et al., 1998; Sangiuolo et al., 1998; Papponen et al., 1999). However, among the MC 
families reported here, the heterozygous carriers of this mutation were generally not affected 
with MC, except in three individuals, I:2 and II:1 in family N10 (Figure 1b, paper I) and  II:5 
in family N04 (Figure 1d, paper I).  The latter two patients had ‘latent’ myotonia. In addition, 
heterozygosity for the p.Arg894X causing mutation was also identified in IV:3 in the 
PROMM family (paper III). This individual carried no CCTG expansion, but reported 
symptoms of muscle stiffness without clinical and electrical myotonia demonstrated (paper 
III). Due to its high allele frequency (0.87%), the c.2680C>T (p.Arg894X) mutation is 
unlikely to cause DMC in our population. However, it might contribute to the relatively high 
prevalence of MC. Larger population studies are needed to investigate this hypothesis.  
 The p.Ala531Val causing mutation seemed to be involved in both RMC and DMC in 
the MC cohort presented here (paper I). None of the heterozygous carriers of this mutation 
were analyzed by sequencing the whole CLCN1 gene. Thus, myotonia might be caused by a 
second unidentified mutation, or, alternatively, by heterozygote manifestation in some of the 
heterozygous carriers. This is consistent with the findings from MC families in Finland 
(Papponen et al., 1999).   
 The clinical outcome of MC, such as age of onset, muscular hypertrophy, site or 
severity of myotonia, myalgia, muscle weakness and disease progression cannot be predicted 
based on the mutant genotype alone. A high fraction of our verified MC patients was 
compound heterozygous (9 of the 15 probands) (paper I). This was observed even in families 
with apparently dominant segregation of myotonia and is consistent with several other studies 
in which a direct sequencing strategy has been applied (Papponen et al., 1999; Trip et al., 
2008). Frequent occurrence of compound heterozygosity and the pronounced allelic 
heterogeneity contribute to the difficulties in determining the genotype-phenotype relationship 
   40 
at the clinical level. In our study, MC patients, who were compound heterozygous, 
experienced more severe muscle stiffness and showed more pronounced clinical and electrical 
myotonia than heterozygous family members. This is in accordance with early studies 
(Mailänder et al., 1996; Plassart-Schiess et al., 1998; Colding-Jørgensen, 2005).   
 A few reports have described the clinical features related to the different genotypes 
(Papponen et al., 1999; Fialho et al., 2007; Dupré et al., 2009). Papponen et al. (1999) 
reported that the p.Ala531Val substitution in a homozygous form or in combination with 
either the p.Phe413Cys or the p.Arg894X substitution was associated with the most severe 
muscular hypertrophy and myotonia. Patients homozygous for the p.Arg894X causing 
mutation rarely experience tongue myotonia, while those homozygous for the p.Ala531Val 
causing mutation had no myotonia during swallowing. However, these observations are 
limited and clinical studies in large cohorts are necessary to validate these and other possible 
genotype correlations. 
  
In vitro systems as tools to understand molecular pathogenesis in MC  
 Functional studies of the disease-causing CLCN1 mutations have enhanced our 
understanding of MC, especially the functional implications of different genotypes underlying 
MC. For example, the p.Arg894X mutant channel conducted reduced Cl- currents with 
otherwise WT characteristics (Meyer-Kleine et al., 1995). When co-expressed with the WT 
CLCN1, the p.Arg894X mutant channel subunit showed only a weak dominant negative 
effect. The Cl- conductance produced by the heterologous channel is close to the border 
between a “recessive” and “dominant” mutation. (Meyer-Kleine et al., 1995). This may 
explain why this mutation could be associated with both DMC and RMC.  
 In a follow up study (paper II), we investigated the functional implication of the 
novel p.Ala331Thr variant identified in our mutation analysis study (paper I). The Alanine 
codon at position 331 is evolutionary conserved in ClC-0, ClC-1 and ClC-2. It is localized in 
the I-J interlink (Dutzler et al. 2002; paper I) (Figure 6). The mutation causes replacement of a 
small hydrophobic side chain (Ala) with a polar one (Thr). How this affects the structure of 
the I-J interlink remains to be elucidated. The whole-cell current recording of the mutant 
channel, by patch clamp technique, was apparently normal (paper II). However, when tested 
under more physiological conditions, there was a clearly rightward shift of the activation 
curve of the mutant channels as compared with the WT channel under identical conditions 
(paper II). The alterations caused by the p.Ala331Thr mutant channel are distinct from any 
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functional effects previously described for other mutations showing the rightward shift of 
open probability. The mutant channel exhibited a novel slow activation gating step. However, 
this gating process was absent in heterodimeric channels when the p.Ala331Thr was co-
expressed with WT CLCN1 (paper II). The patient with the p.Ala331Thr also carried a 
putative splice site mutation c.2284+5C>T on the other allele. The electrophysiological 
features exhibited by the mutant channels were in agreement with a recessive inheritance. 
However, in retrospect as discussed above, c.2284+5C>T was shown to be a polymorphism, 
which leaves the p.Ala331Thr variant to cause DMC rather than RMC. This is in contrast to 
the conclusion based upon the functional expression study (paper II). In addition to myotonia, 
the patient had spastic paraparesis. To which extent, if at all, this novel gating property of the 
p.Ala331Thr mutant channel might contribute to this clinical feature is currently unknown.  
  With regard to our findings, in vitro electrophysiological studies of other ClC-1 
variants have also given controversial results, or results that have been difficult to interpret. 
Even mutations with electrophysiological characteristics consistent with a dominant 
inheritance pattern have been found in recessive pedigrees (Pusch et al., 1995; Wollnik et al., 
1997; Kubisch et al., 1998; Aromataris et al., 2001; Pusch, 2002). Several mutations involved 
in RMC showed little or no evidence of abnormal channel function in heterologous expression 
systems (Wollnik et al., 1997; Pusch et al., 2002; Simpson et al., 2004).  Discrepant results 
concerning the same mutation in similar types of expression systems have also been reported. 
Wagner and coworkers (1996) could not detect expression of the p.Tyr150Cys substitution in 
Xenopus oocytes, while Wollnik et al. (1997) reported normal channel function in the same 
expression system. The endogenous expression in the different cells or cell lines has been 
thought to be negligible. However, heterologous expression systems do not necessarily 
reproduce the true ‘physiological’ conductance of the channel as mechanisms present in the 
intact skeletal muscle may not be faithfully reproduced. Papponen and colleagues (2008) 
demonstrated that the p.Phe413Cys and p.Ala531Val substitutions, but not the p.Arg894X 
substitution showed defects in trafficking of the channel protein from the endoplasmic 
reticulum (ER) to the Golgi apparatus. This may explain the minimal shift in GCl upon 
functional expression of the p.Phe413Cys mutant channel in vitro (Zhang et al. 2000b). Thus, 
one should be aware that decay or impaired intracellular transport of mutant proteins may, in 
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Challenges in classification of MC 
 The marked phenotypic heterogeneity of myotonia in our MC population is in 
accordance with what has previously been reported. In the patient material presented here 
clinical differentiation between Becker’s and Thomsen’s myotonia in single patients seems to 
be difficult despite the earlier described clinical distinction between DMC and RMC (Becker, 
1977; Heatwole and Moxley, 2007; Mankodi, 2008). Age of onset and site of onset (upper or 
lower limb) of myotonia showed variations and considerable overlap with respect to the 
classical clinical criteria for Thomsen’s and Becker’s myotonia. Muscle hypertrophy of lower 
extremities is usually equally present in both types. The peculiar transient muscle weakness, 
described in RMC, was rarely observed in our patient material, despite the fact that the 
majority of our families most likely had recessively inherited myotonia. Thus, the clinical 
classification as either Thomsen’s or Becker’s disease in our MC population was entirely 
based on the inheritance patterns in each family. This is in accordance with conclusions based 
on a study of a Dutch cohort of patients with NDMs (Trip et al., 2009). In that study no 
statistically significant differences were observed between clinical phenotypes of RMC and 
DMC. Transient muscle weakness was described as a unique feature that could distinguish 
ClCh from NaCh. However, it could not distinguish RMC from DMC in the Dutch cohort. 
Fialho and co-worker (2007) studied a large British cohort of MC patients. No significant 
differences were observed with regard to age of onset or site of onset between RMC and 
DMC. However, they found that transient muscle weakness and muscle hypertrophy occurred 
more frequently in RMC than in DMC.  
 In the majority of the fifteen Norwegian MC families myotonia was inherited in an 
autosomal recessive fashion (paper I), which is consistent with that of the Finnish MC 
families (Baumann et al, 1998; Papponen et al., 1999). Five families showed autosomal 
dominant inheritance. Of these, two families (family N11 and N15, paper I; paper III) were 
later proven to have DM2. Two other families (N01 and N04, paper I) showed 
pseudodominant inheritance, as several spouses introduced mutations into the family, in 
similarity to one Finnish MC family (Papponen et al, 1999). In the last family (N06, paper I) 
no CLCN1 mutation could be identified in the proband. In a Dutch population of 32 
genetically confirmed MC patients, only two of them were diagnosed with DMC (Trip et al., 
2009), whereas Fialho and coworkers (2007) reported an unexpectedly high proportion of 
DMC in a large British MC population. Dissimilar mode of inheritance among geographically 
separated MC populations may reflect different spectrums of CLCN1 mutations. It should be 
noted that after the genetic bases of myotonia were discovered, several clinical aspects were 
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reconsidered and many of the original DMC families turned out to have NaCh (Koch et al, 
1989; Wagner et al., 1998; Jurkat-Rott et al., 2010a). Thus, some DMC cases in which 
mutations in CLCN1 remained to be identified may actually have NaCh.  
 Family pedigrees have to be interpreted with caution. The pedigree pattern can easily 
be misinterpreted since variable penetrance has been described for several dominantly 
inherited CLCN1 mutations (Colding-Jørgensen, 2005). Some patients may have very mild 
symptoms, and ‘latent myotonia’ is not uncommon among MC patients. In addition, our 
studies showed that the inheritance pattern of myotonia in some pedigrees may be obscure 
(paper I). Examples are given by the pedigrees N01 (paper I) presenting with apparently 
dominant segregation of myotonia. However, molecular analysis revealed different 
combinations of two recessively inherited CLCN1 mutations with four independent mutant 
alleles segregating with myotonia in the family. Two of the mutant alleles were introduced by 
married-in individuals as a consequence of high carrier frequency of some mutations (paper 
I).  
 These data indicate that the earlier classification of MC into dominant Thomsen and 
recessive Becker myotonia is to date less valuable and may sometimes be misleading. One 
should not simply rely on the inheritance pattern in the family when assessing risk for 
transmission of MC. In general, the combination of clinical, genetic and functional studies 
provides a more profound basis for a more accurate genetic counseling. 
  
The impact of CLCN1 mutation on the DM2 phenotype  
 CLCN1 mutations have also been identified in DM2 patients (Mastaglia et al., 1998; 
Lamont et al., 2004; Suominen et al., 2008). Suominen and colleagues (2008) reported that 
about 5% of the German and 3% of the Finnish DM2 patients carry the most frequent 
p.Arg894X causing CLCN1 mutation, whereas, the carrier frequency in the normal German 
and Finnish population was 1% and 1.3%, respectively. In addition, 2% of the Finnish DM2 
population carries the p.Phe413Cys causing mutation, compared to 0.7% in the normal 
population. Until now, no CLCN1 mutations have been reported in DM1 patients. The 
frequencies of CLCN1 mutations within the DM2 population are not expected to be different 
from the normal population. The disproportional frequency of CLCN1 mutations within the 
DM2 patients might simply reflect a selection bias towards the diagnosis of DM2 patients at 
the severe end of the phenotypic spectrum, as suggested by Souminen et al. (2008).  
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 The first identified Norwegian PROMM family harbored the p.Arg894X causing 
mutation in heterozygous form in all affected family members. Haplotype analysis seemed to 
exclude the DM2 locus as the disease locus, since the only healthy son (IV:I, paper III) as 
well as his affected brother (IV:3, paper III) inherited the same haplotype from their affected 
mother (III:2, paper III). However, after the genetic cause of DM2 was found, the 
pathological (CCTG)n expansion was subsequently identified both in III:2 and IV:2, while 
both IV:1 and IV:3 had normal DM2 alleles (data not shown). Thus, heterozygosity for the 
p.Arg894X causing mutation may contribute to the myotonic phenotype of IV:3 in this 
family. Alternatively, another unidentified CLCN1 mutation may exist that may account for 
the difference in phenotypic expression in IV:1 and IV:3. 
 In the genetically verified DM2 family (family N15, paper I; paper IV), a coincident 
heterozygous p.Phe413Cys causing CLCN1 mutation was identified in some of the family 
members. The affected family members with both the CNBP expansion and the p.Phe413Cys 
substitution exhibited more severe myotonia both subjectively, clinically and electrically 
compared to patients harboring the CNBP expansion alone. Further clinical investigations are 
needed to establish if CLCN1 mutations act as modifying factors in manifestations of DM2.  
 Like MC, DM2 is probably underdiagnosed in the general population because of the 
mild character in some patients. Furthermore, DM2 patients with very mild symptoms may 
present with a clinical picture that is very difficult to distinguish from NDMs such as MC 
(paper IV). To date, the prevalence of misdiagnosed DM2 in the MC, especially the DMC, 
population is unknown. Thus, the clinically diagnosed MC patients heterozygous for doubtful 
CLCN1 mutations, or patients in whom CLCN1 mutations remain undetected, should be 
reconsidered carefully for DM2 diagnostics. This is important since the extramuscular 
manifestations of DM2 have important implications for prognosis and management. 
 
Modifying factors of myotonia 
 Several lines of evidence indicate the existence of additional modifying factors 
which may account for the broad clinical manifestations and severity of myotonia (Thomsen 
1876; Becker, 1977; Deymeer et al, 1999; Simpson et al., 2004; Colding-Jørgensen, 2005). 
The intrafamilial phenotypic variation seen in patients sharing the same genotype (paper I) is 
in agreement with these previous observations.  
Lower clinical expressivity in females has been well documented (Becker, 1977; 
Mailänder et al., 1996; Baumann et al., 1998; Deymeer et al., 1999). In one branch of our 
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DM2 family (paper IV) all affected females developed myotonia during pregnancies, and the 
myotonia never disappeared after delivery. This is in contrast to the previous observations 
(Lacomis et al., 1999; Newman et al., 1999; Rudnik-Schöneborn et al., 2006). Dupré and co-
workers (2009) reported significant improvement of myotonia after menopause. These 
observations indicate that hormonal factors may influence the clinical manifestations of 
myotonia. Recently, both testosterone and progesterone were shown to rapidly and reversibly 
inhibit WT ClC-1 channels expressed in the Xenopus oocytes (Fialho et al., 2008).  
Other possible modifying candidates could be the additional Cl- channels expressed 
in the muscle with similar structure, especially ClC-2 and ClC-4. The ClC-2 was shown to 
have the ability to form heteromultimeric channels with ClC-1 (Lorenz et al., 1996). They 
may partially compensate for the absence of functional ClC-1 in myotonia congenita. The 
CLCN4 gene is located on the X chromosome. One might speculate about its role in reduced 
clinical expressivity of myotonia in females. 
Knowledge on the possible involvement of environmental modifying factors for 
myotonia is lacking. However, myotonic episodes might be triggered by factors such as stress 
and mental discomfort. This indicates that the emotional state of a patient might play a role in 
manifestation of myotonia. 
 
Future challenges 
 The crystal structure of prokaryote ClCs has been solved (Dutzler, 2002) and its 3-
dimensional structure has facilitated the understanding of the functional implications of the 
different CLCN1 mutations on channel function. The ClC 3D structure may provide further 
aid in understanding the genotype - phenotype relationship in MC. The explanations for 
variable expressivity and incomplete penetrance are not understood. The mechanism 
underlying the warm-up phenomenon is still unclear. The intriguing inheritance of MC needs 
to be clarified. Solving these questions will have a great impact on genetic counseling. 
 Few studies have been designed in order to investigate the genotype – phenotype 
relationship in MC at the clinical level. Standardization of the definition of affected status of 
myotonia as well as that of assessment of symptoms, clinical signs and EMG measures are 
important for future investigations. To genetically exclude DM2 in MC cases with dominant 
inheritance and doubtful CLCN1 mutation is elemental. In this respect, challenges also exist in 
promoting improved awareness of MC and DM among health care providers. 
 The knowledge about the molecular mechanisms underlying DM has greatly 
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increased during the past decade. However, many questions concerning the pathophysiology 
still remain unanswered. The comprehensive mechanisms underlying the whole spectrum of 
DM manifestation as well as the possible connection between the different pathways need to 
be elucidated. Future research is also required to establish if there exist other DM loci.  
 Therapy for DM and myotonia is currently supportive aiming at ameliorating 
symptoms. Randomized control clinical trials on antimyotonic drugs are underway 
(http://clinicaltrials.gov). However, accurate outcome measures that reliably assess the 
myotonic responses quantitatively need to be established. Our understanding of DM 
pathologies has advanced the possibility for more direct treatments aiming at the underlying 
genetic defects. As of to date, reports based on early stage gene therapy approaches are few, 
but promising (Rogers et al., 2002; Wheeler et al., 2007; Cleland and Grigg, 2008; Matthews 
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Pedigrees of the fifteen Northern-Norwegian MC families (N01-15) and three Swedish MC families (S01-03) studied.  
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Appendix II 
Allele frequencies of selected mutations in the Fennoscandian populations. 
Number of alleles studied  
in the normal population  
Number of alleles  
carrying the mutation 
 
Mutations 




p.Ala331Thr 88   88 0    0 
p.Phe413Cys 92 94 100 286 0 0 0 0 0 
p.Ala531Val 188 82 86 356 0 0 1 1 0.3 
p.Arg894X 194 162 100 456 2 1 1 4 0.87 
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